Why Sutro Biopharma Blasted 33% Higher on Friday
Sutro Biopharma (NASDAQ: STRO) was a rock star stock on Friday, with a mighty price increase on the back of some very good news released on Thursday. The company's STRO-002 cancer drug candidate showed impressive results in an early-phase clinical study involving patients with ovarian cancer.
Updated data from the phase 1 clinical trial of STRO-002 showed that of the 31 evaluable participants, 23 reached disease control after 12 weeks, with 18 doing so after 16 weeks. Ten patients met response evaluation criteria in solid tumors (RECIST), a measurement of tumor development gauging how a cancer patient responds to a certain treatment criteria. The drug was well-tolerated by participants in the trial.
Source Fool.com
